Reducing the risk of metastatic relapse in patients with resectable soft tissue sarcomas is crucial for improving outcomes, because metastasis is the primary cause of mortality in this population.

LOUISVILLE, Ky. -- Large tumor size and high disease grade were associated with an increased risk of early cancer-related ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

Patients with dMMR colon cancer in a trial for two neoadjuvant cycles of nivolumab/ipilimumab or nivolumab/relatlimab, had ...

No delay of surgery was observed in either cohort. “These promising pCR rates met the threshold to expand our cohorts to ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) ...

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant ...

The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for ...

Perioperative chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC) shows promising long-term benefits with ...